NASDAQ:VYNE

VYNE Therapeutics Competitors

$5.34
-0.12 (-2.20 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.15
Now: $5.35
$5.43
50-Day Range
$5.46
MA: $6.91
$7.89
52-Week Range
$4.84
Now: $5.35
$13.20
Volume985,334 shs
Average Volume2.20 million shs
Market Capitalization$274.35 million
P/E RatioN/A
Dividend YieldN/A
Beta0.97

Competitors

VYNE Therapeutics (NASDAQ:VYNE) Vs. PLRX, CNST, KNSA, ARCT, ZGNX, and PRAX

Should you be buying VYNE stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to VYNE Therapeutics, including Pliant Therapeutics (PLRX), Constellation Pharmaceuticals (CNST), Kiniksa Pharmaceuticals (KNSA), Arcturus Therapeutics (ARCT), Zogenix (ZGNX), and Praxis Precision Medicines (PRAX).

Pliant Therapeutics (NASDAQ:PLRX) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, earnings, risk and institutional ownership.

Insider & Institutional Ownership

79.5% of Pliant Therapeutics shares are held by institutional investors. Comparatively, 50.1% of VYNE Therapeutics shares are held by institutional investors. 2.2% of VYNE Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings for Pliant Therapeutics and VYNE Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pliant Therapeutics00503.00
VYNE Therapeutics00603.00

Pliant Therapeutics presently has a consensus price target of $45.50, suggesting a potential upside of 52.02%. VYNE Therapeutics has a consensus price target of $19.50, suggesting a potential upside of 264.83%. Given VYNE Therapeutics' higher probable upside, analysts clearly believe VYNE Therapeutics is more favorable than Pliant Therapeutics.

Valuation and Earnings

This table compares Pliant Therapeutics and VYNE Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pliant Therapeutics$57.05 million18.75$-630,000.00N/AN/A
VYNE Therapeutics$10.64 million25.79$-73,700,000.00($3.09)-1.73

Pliant Therapeutics has higher revenue and earnings than VYNE Therapeutics.

Profitability

This table compares Pliant Therapeutics and VYNE Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pliant Therapeutics20.83%16.55%8.33%
VYNE TherapeuticsN/A-331.83%-210.68%

Summary

Pliant Therapeutics beats VYNE Therapeutics on 6 of the 10 factors compared between the two stocks.

VYNE Therapeutics (NASDAQ:VYNE) and Constellation Pharmaceuticals (NASDAQ:CNST) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Insider & Institutional Ownership

50.1% of VYNE Therapeutics shares are held by institutional investors. 2.2% of VYNE Therapeutics shares are held by insiders. Comparatively, 10.6% of Constellation Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for VYNE Therapeutics and Constellation Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VYNE Therapeutics00603.00
Constellation Pharmaceuticals02502.71

VYNE Therapeutics currently has a consensus target price of $19.50, suggesting a potential upside of 264.83%. Constellation Pharmaceuticals has a consensus target price of $45.2857, suggesting a potential upside of 103.17%. Given VYNE Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe VYNE Therapeutics is more favorable than Constellation Pharmaceuticals.

Earnings and Valuation

This table compares VYNE Therapeutics and Constellation Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VYNE Therapeutics$10.64 million25.79$-73,700,000.00($3.09)-1.73
Constellation PharmaceuticalsN/AN/A$-85,550,000.00($3.04)-7.33

VYNE Therapeutics has higher revenue and earnings than Constellation Pharmaceuticals. Constellation Pharmaceuticals is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

VYNE Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Constellation Pharmaceuticals has a beta of 2.8, suggesting that its share price is 180% more volatile than the S&P 500.

Profitability

This table compares VYNE Therapeutics and Constellation Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VYNE TherapeuticsN/A-331.83%-210.68%
Constellation PharmaceuticalsN/A-28.88%-24.98%

Summary

VYNE Therapeutics beats Constellation Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

VYNE Therapeutics (NASDAQ:VYNE) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Insider & Institutional Ownership

50.1% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 42.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. 2.2% of VYNE Therapeutics shares are held by insiders. Comparatively, 70.6% of Kiniksa Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for VYNE Therapeutics and Kiniksa Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VYNE Therapeutics00603.00
Kiniksa Pharmaceuticals00303.00

VYNE Therapeutics currently has a consensus target price of $19.50, suggesting a potential upside of 264.83%. Kiniksa Pharmaceuticals has a consensus target price of $37.00, suggesting a potential upside of 136.72%. Given VYNE Therapeutics' higher possible upside, equities analysts plainly believe VYNE Therapeutics is more favorable than Kiniksa Pharmaceuticals.

Earnings and Valuation

This table compares VYNE Therapeutics and Kiniksa Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VYNE Therapeutics$10.64 million25.79$-73,700,000.00($3.09)-1.73
Kiniksa PharmaceuticalsN/AN/A$-161,870,000.00($2.99)-5.23

VYNE Therapeutics has higher revenue and earnings than Kiniksa Pharmaceuticals. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

VYNE Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.03, suggesting that its share price is 97% less volatile than the S&P 500.

Profitability

This table compares VYNE Therapeutics and Kiniksa Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VYNE TherapeuticsN/A-331.83%-210.68%
Kiniksa PharmaceuticalsN/A-53.65%-49.11%

Summary

VYNE Therapeutics beats Kiniksa Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

VYNE Therapeutics (NASDAQ:VYNE) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Insider & Institutional Ownership

50.1% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 74.3% of Arcturus Therapeutics shares are held by institutional investors. 2.2% of VYNE Therapeutics shares are held by insiders. Comparatively, 12.6% of Arcturus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for VYNE Therapeutics and Arcturus Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VYNE Therapeutics00603.00
Arcturus Therapeutics25402.18

VYNE Therapeutics currently has a consensus target price of $19.50, suggesting a potential upside of 264.83%. Arcturus Therapeutics has a consensus target price of $70.6667, suggesting a potential upside of 75.22%. Given VYNE Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe VYNE Therapeutics is more favorable than Arcturus Therapeutics.

Earnings and Valuation

This table compares VYNE Therapeutics and Arcturus Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VYNE Therapeutics$10.64 million25.79$-73,700,000.00($3.09)-1.73
Arcturus Therapeutics$20.79 million50.98$-25,990,000.00($2.15)-18.76

Arcturus Therapeutics has higher revenue and earnings than VYNE Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

VYNE Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 3.01, suggesting that its share price is 201% more volatile than the S&P 500.

Profitability

This table compares VYNE Therapeutics and Arcturus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VYNE TherapeuticsN/A-331.83%-210.68%
Arcturus Therapeutics-506.70%-52.32%-33.21%

Summary

Arcturus Therapeutics beats VYNE Therapeutics on 9 of the 14 factors compared between the two stocks.

VYNE Therapeutics (NASDAQ:VYNE) and Zogenix (NASDAQ:ZGNX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Insider & Institutional Ownership

50.1% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 96.6% of Zogenix shares are held by institutional investors. 2.2% of VYNE Therapeutics shares are held by insiders. Comparatively, 3.5% of Zogenix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for VYNE Therapeutics and Zogenix, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VYNE Therapeutics00603.00
Zogenix01502.83

VYNE Therapeutics currently has a consensus target price of $19.50, suggesting a potential upside of 264.83%. Zogenix has a consensus target price of $58.25, suggesting a potential upside of 206.58%. Given VYNE Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe VYNE Therapeutics is more favorable than Zogenix.

Earnings and Valuation

This table compares VYNE Therapeutics and Zogenix's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VYNE Therapeutics$10.64 million25.79$-73,700,000.00($3.09)-1.73
Zogenix$3.65 million290.13$-419,500,000.00($3.90)-4.87

VYNE Therapeutics has higher revenue and earnings than Zogenix. Zogenix is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

VYNE Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Zogenix has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500.

Profitability

This table compares VYNE Therapeutics and Zogenix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VYNE TherapeuticsN/A-331.83%-210.68%
Zogenix-8,758.48%-53.91%-36.49%

Summary

VYNE Therapeutics beats Zogenix on 8 of the 14 factors compared between the two stocks.

VYNE Therapeutics (NASDAQ:VYNE) and Praxis Precision Medicines (NASDAQ:PRAX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Insider & Institutional Ownership

50.1% of VYNE Therapeutics shares are held by institutional investors. 2.2% of VYNE Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for VYNE Therapeutics and Praxis Precision Medicines, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VYNE Therapeutics00603.00
Praxis Precision Medicines00403.00

VYNE Therapeutics currently has a consensus target price of $19.50, suggesting a potential upside of 264.83%. Praxis Precision Medicines has a consensus target price of $60.3333, suggesting a potential upside of 120.44%. Given VYNE Therapeutics' higher possible upside, equities analysts plainly believe VYNE Therapeutics is more favorable than Praxis Precision Medicines.

Earnings and Valuation

This table compares VYNE Therapeutics and Praxis Precision Medicines' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VYNE Therapeutics$10.64 million25.79$-73,700,000.00($3.09)-1.73
Praxis Precision MedicinesN/AN/AN/AN/AN/A

Praxis Precision Medicines has lower revenue, but higher earnings than VYNE Therapeutics.

Profitability

This table compares VYNE Therapeutics and Praxis Precision Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VYNE TherapeuticsN/A-331.83%-210.68%
Praxis Precision MedicinesN/AN/AN/A

Summary

VYNE Therapeutics beats Praxis Precision Medicines on 5 of the 7 factors compared between the two stocks.


VYNE Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$29.93-2.4%$1.07 billion$57.05 million0.00Insider Selling
News Coverage
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$22.29-4.5%$1.07 billionN/A-8.23Unusual Options Activity
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$15.63-5.2%$1.07 billionN/A-6.59Gap Down
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$40.33-2.0%$1.06 billion$20.79 million-13.91News Coverage
Zogenix logo
ZGNX
Zogenix
1.7$19.00-3.5%$1.06 billion$3.65 million-2.00Analyst Upgrade
News Coverage
Gap Down
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$27.37-5.6%$1.06 billionN/A0.00Increase in Short Interest
Lockup Expiration
News Coverage
MannKind logo
MNKD
MannKind
1.4$4.18-2.9%$1.04 billion$63.04 million-19.90Increase in Short Interest
Gap Down
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$9.98-4.0%$1.03 billion$120,000.00-3.70Analyst Report
News Coverage
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$50.68-2.1%$1.02 billion$122.47 million-27.85Analyst Downgrade
News Coverage
Prothena logo
PRTA
Prothena
2.1$24.85-3.2%$994.15 million$810,000.00-9.71Increase in Short Interest
News Coverage
Gap Down
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$19.71-5.2%$989.07 millionN/A-6.48Increase in Short Interest
News Coverage
Gap Down
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.43-1.1%$988.27 million$800.40 million23.05
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$23.51-6.8%$986.46 millionN/A-8.11Insider Selling
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$20.41-2.8%$984.50 million$1.52 million-10.86Increase in Short Interest
News Coverage
Gap Down
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.34-1.0%$950.61 millionN/A-12.60
Radius Health logo
RDUS
Radius Health
1.1$19.71-0.2%$924.28 million$173.32 million-8.08
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.67-0.7%$914.90 million$227.19 million46.31Analyst Upgrade
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$17.45-0.5%$897.94 millionN/A0.00
Annexon logo
ANNX
Annexon
1.9$23.42-2.2%$893.66 millionN/A0.00Increase in Short Interest
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.6$34.95-0.1%$858.83 millionN/A-10.37Analyst Report
News Coverage
Merus logo
MRUS
Merus
1.6$22.52-1.7%$858.62 million$31.13 million-7.34Analyst Report
Ardelyx logo
ARDX
Ardelyx
1.6$8.69-0.3%$857.53 million$5.28 million-8.60High Trading Volume
Unusual Options Activity
News Coverage
Affimed logo
AFMD
Affimed
1.6$9.51-0.3%$839.98 million$23.96 million-16.12Earnings Announcement
Analyst Revision
News Coverage
ESSA Pharma logo
EPIX
ESSA Pharma
1.6$24.82-5.4%$838.42 millionN/A-22.98
Epizyme logo
EPZM
Epizyme
1.8$8.10-1.6%$824.46 million$23.80 million-3.63
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.7$17.30-0.3%$820.59 million$322.36 million123.57
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$23.27-0.8%$819.20 million$296.70 million47.49Analyst Revision
News Coverage
Humanigen logo
HGEN
Humanigen
1.7$14.73-5.6%$787.79 millionN/A0.00Increase in Short Interest
Gap Down
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.33-2.7%$782.70 millionN/A0.00Increase in Short Interest
Gap Down
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.2$27.02-0.1%$755.02 million$148.36 million-7.02Analyst Revision
News Coverage
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.05-3.2%$728.99 million$322.07 million-4.81Decrease in Short Interest
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$9.71-0.2%$728.84 million$40.89 million-3.35
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.33-2.7%$716.63 million$150,000.00-4.76
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$19.63-1.9%$702.93 million$6.83 million-20.24
Chimerix logo
CMRX
Chimerix
1.3$8.18-1.6%$700.85 million$12.52 million-14.35Analyst Upgrade
Increase in Short Interest
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.71-7.0%$688.35 million$2.22 million-15.94Gap Down
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$29.45-1.8%$680 million$13.80 million-14.23
Veru logo
VERU
Veru
1.4$9.42-1.8%$677.41 million$42.59 million-33.64Analyst Report
Analyst Revision
News Coverage
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$15.90-4.2%$673.79 million$17.26 million-4.42Analyst Revision
News Coverage
Kadmon logo
KDMN
Kadmon
1.8$3.92-0.5%$673.52 million$5.09 million-6.53Analyst Downgrade
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$26.88-1.2%$671.22 million$19.56 million-19.34News Coverage
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$20.28-1.3%$669.56 million$252 million-2.07High Trading Volume
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.49-4.2%$641.23 millionN/A-2.38Analyst Downgrade
Increase in Short Interest
News Coverage
Gap Down
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.98-2.0%$625.09 million$143.01 million-1.14
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$32.60-1.0%$623.12 million$9.64 million-5.31
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$11.56-0.0%$616.55 millionN/A-4.64Analyst Revision
News Coverage
Gap Down
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.58-5.6%$609.03 million$59.29 million-23.87Increase in Short Interest
Gap Down
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$18.61-0.5%$600.36 millionN/A-9.90Analyst Report
High Trading Volume
News Coverage
AnaptysBio logo
ANAB
AnaptysBio
1.5$21.72-1.6%$594.39 million$8 million-8.01News Coverage
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$24.45-3.1%$594.33 million$12.69 million-11.75Increase in Short Interest
Gap Down
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.